Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Date:3/14/2012

including their significance and what they were intended to address, refine and assess; the FDA advisory committee meeting and the discussion on the NDA resubmission; the potential approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; lorcaserin's patent coverage; cost-containment efforts; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when anticipated; the EU application is subject to acceptance and confirmation by the EU regulatory agency that it is sufficient to permit a substantive review; the FDA may not complete its review of the lorcaserin application by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
3. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
4. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
5. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
7. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
9. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
10. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 A pharmaceutical executive in ... with three issues he wanted the research and consulting ... external personnel (especially for secondary research) to maximize efficiency ... of increased workload , Automation of market research ... , How to implement and manage those automated ...
(Date:9/19/2014)... 19, 2014  Today DePuy Synthes Companies of ... plating systems featuring its proprietary variable angle locking ... trajectory to match patient anatomy and fracture pattern ... The systems are being introduced in conjunction with ... and the International Federation of Foot & Ankle ...
(Date:9/19/2014)... 2014 "Copay coupons," a drug ... brand drugs among patients with prescription drug coverage, may now ... new report  from the Department of Health ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... by the federal government. The ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2
(Date:9/19/2014)... 19, 2014 BearCom, a nationwide ... detailed the key role played by instant, one-to-one ... the healthcare industry. , “In healthcare, speed ... – and in emergency situations, can save precious ... and death,” said Hugh Johnston, Product & Purchasing ...
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 On ... News at the Platinum PR and Top Places to ... in New York City. Camino received honorable mentions in ... Campaign” — for its work elevating Latina voices in ... incredible organization and be a part of its efforts ...
(Date:9/19/2014)... More than half of human cancers have ... yet how these signals are controlled during tumor ... PhD, MD, and Svetlana Fayngerts, PhD, both researchers ... at the Perelman School of Medicine, University of ... described oncogenic protein, promotes cancer by targeting these ...
(Date:9/19/2014)... AZ (PRWEB) September 19, 2014 Hastings and ... 30 years in the industry, announces a record number of ... handles a wide variety of serious injury cases as well ... along with dog bite related accident cases and others. Having ... and Hastings has stood the test of time when it ...
Breaking Medicine News(10 mins):Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2
... Mercedes Walton, CEO of Cryo-Cell International, one of the ... progress to date and encouraging continued momentum for existing bills through ... Cord Blood Banking Act," and H.R. 2107, the "Cord Blood Education ... progress from the first half of the year to enable and ...
... Sociological Association,s 104th annual meeting, will be the subject ... present research and explore the politics, history, health and ... More than 5,000 sociologists will convene in the ... New Politics of Community," the meeting,s theme. In addition ...
... , SAN DIEGO, July 6 ADVENTRX Pharmaceuticals, Inc. ... it has completed the previously announced sale of shares ... to a registered direct offering to a single institutional ... percent, or approximately $340,250, of the gross proceeds will ...
... showed muscle fiber damage even after halting drugs, researchers say ... used to lower cholesterol, may cause structural damage to the ... study has found. , The damage may occur even when ... and may persist even after statin use is halted, according ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
... Inc. (Nasdaq: SLTM ), a global leader in ... an amendment with Silicon Valley Bank, a member company of ... the company,s credit facility has been expanded from $9 million ... the secured revolving loan facility to $8.0 million, an amendment ...
Cached Medicine News:Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 2Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 3Health News:Sociologists to turn the sociological eye on San Francisco 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 3Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 4Health News:Statins May Cause Muscle Damage in Some Patients 2Health News:Statins May Cause Muscle Damage in Some Patients 3Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 2Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 3
... Advanced Magnetics' oral gastrointestinal imaging agent used ... from other abdominal structures and physiology. MRI ... abdomen without contrast agents is difficult because ... distinguished from the loops of the bowel. ...
... only isosmolar contrast medium (IOCM) available in the ... blood, VISIPAQUE was designed for patient safety and ... formulated with sodium and calcium in a ratio ... approval for use in children over one year ...
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
Hand surgery basic instrument set...
Medicine Products: